Concepedia

Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea

Hiroyoshi Takemoto, Junichi Nishimura, Takamichi Komori, Ho Min Kim, Hirofumi Ota, Rei Suzuki, Masakazu Ikenaga, Masataka Ikeda, Hirofumi Yamamoto, Taroh Satoh,

International Journal of Clinical Oncology · 2016 · 35 citations · 16 references

DOI

Concepts

References

16

Hepatobiliary Cancers

Al B. Benson, Thomas A. Abrams, Edgar Ben‐Josef et al. · Journal of the National Comprehensive Cancer Network · 2009 · 2.3K citations · Full text

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy

David Warr, Paul J. Hesketh, Richard J. Gralla et al. · Journal of Clinical Oncology · 2005 · 464 citations

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

Paul J. Hesketh, Matti Aapro, James C. Street et al. · Supportive Care in Cancer · 2009 · 169 citations

, , +12

Risk factors of chemotherapy‐induced nausea and vomiting: Index for personalized antiemetic prophylaxis

Ikuo Sekine, Yoshihiko Segawa, Kaoru Kubota et al. · Cancer Science · 2013 · 165 citations · Full text

, , +21

Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan

International Journal of Clinical Oncology · 2015 · 154 citations

, , +10